- ►wanfang.gov.tw [DOC] RE Amori, J Lau, AG Pittas - Jama, 2007 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 240 - Related articles - BL Direct - All 8 versions
DC Klonoff, JB Buse, LL Nielsen, X Guan, … - Current Medical Research and Opinion®, 2007 - informahealthcare.com Background: Exenatide, an incretin mimetic for adjunctive treatment of type 2
diabetes (T2DM), reduced hemoglobin A1c (A1C) and weight in clinical trials. The
objective of this study was to evaluate the effects of ≥3 years exenatide ... Cited by 91 - Related articles - BL Direct - All 7 versions
DJ Drucker, JB Buse, K Taylor, DM Kendall, M … - The Lancet, 2008 - Elsevier A 30-week, randomised, non-inferiority study compared a long-acting release
formulation of exenatide 2 mg administered once weekly to 10 μg exenatide
administered twice a day, in 295 patients with type 2 diabetes (haemoglobin ... Cited by 36 - Related articles - All 4 versions
- ►qub.ac.uk [PDF] BD Green, PR Flatt - Best Practice & Research Clinical Endocrinology & …, 2007 - Elsevier The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are physiological gut peptides with
insulin-releasing and extrapancreatic glucoregulatory actions. Incretin ... Cited by 29 - Related articles - All 17 versions
A Barnett - Expert Opin. Pharmacother., 2007 - informahealthcare.com Exenatide is the first in a new class of compounds, which possess similar
activity to the naturally-occurring hormone glucagon-like peptide-1 (GLP-1). It
mirrors many of the effects of GLP-1, improving glycaemic control through a ... Cited by 25 - Related articles - BL Direct - All 8 versions
RA DeFronzo, T Okerson, P Viswanathan, X … - Current Medical Research and Opinion®, 2008 - informahealthcare.com Methods: This double-blind, randomized cross-over, multi-center study was
conducted in metformin-treated T2D patients: 54% female; BMI: 33 ± 5 kg/m 2 ;
HbA 1c : 8.5 ± 1.2%; 2-h PPG: 245 ± 65 mg/dL. Patients received exenatide ... Cited by 26 - Related articles - All 6 versions
S Madsbad, T Krarup, CF Deacon, JJ Holst - Current Opinion in Clinical Nutrition & Metabolic Care, 2008 - journals.lww.com Recent findings: The injectable glucagon-like peptide-1 receptor agonists
exenatide significantly improves glycaemic control, with average reductions in
haemoglobin A1c of about 1.0%, fasting plasma glucose of about 1.4 mmol/l, ... Cited by 23 - Related articles - All 2 versions
JA Batsis, RE Nieto-Martinez, F Lopez- … - Clinical Pharmacology and Therapeutics, 2007 - ucilmsa.org The metabolic syndrome (MetS) encompasses a constellation of metabolic
abnormalities that are thought to place patients at higher risk for the
development of diabetes and cardiovascular (CV) disease. The underlying ... Cited by 22 - Related articles - View as HTML - All 4 versions
- ►endojournals.org CW Chia, JM Egan - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc Evidence Synthesis: Exenatide and liraglutide are injection based. Three-year
follow-up data on exenatide showed a sustained weight loss and glycosylated
hemoglobin (HbA 1c ) reduction of 1%. Nausea and vomiting are common. ... Cited by 20 - Related articles - All 5 versions
SE Inzucchi, DK McGuire - Circulation, 2008 - Am Heart Assoc This is the second of a 2-part series focusing on newer therapies for type 2
diabetes and their cardiovascular implications. In the first segment, we
reviewed the thiazolidinediones, highlighting emerging data concerning ... Cited by 21 - Related articles - All 6 versions
